What The Study Did: This randomized clinical trial compared the outcomes of heart attack, stroke or death from cardiovascular causes among 6,000 patients with type 2 diabetes who were treated with the glucose-lowering medications linagliptin or glimepiride.
To access the embargoed study: Visit our For The Media website at this link https:/
Authors: Nikolaus Marx, M.D., of Aachen University in Aachen, Germany, is the corresponding author.
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Media advisory: The full study and editorial are linked to this news release. This study is being released to coincide with presentation at the European Association for the Study of Diabetes annual meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time: https:/
JAMA Network Media Relations